Rock Springs Capital Management Lp buys $18,872,000 stake in Theravance Biopharma Inc (TBPH)

Theravance Biopharma Inc (TBPH) : Rock Springs Capital Management Lp scooped up 49,500 additional shares in Theravance Biopharma Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 700,000 shares of Theravance Biopharma Inc which is valued at $18,872,000.Theravance Biopharma Inc makes up approximately 1.33% of Rock Springs Capital Management Lp’s portfolio.

Other Hedge Funds, Including , Highbridge Capital Management sold out all of its stake in TBPH during the most recent quarter. The investment firm sold 17,976 shares of TBPH which is valued $484,633.Norges Bank reduced its stake in TBPH by selling 588,866 shares or 58.87% in the most recent quarter. The Hedge Fund company now holds 411,390 shares of TBPH which is valued at $11,091,074. Theravance Biopharma Inc makes up approx 0.01% of Norges Bank’s portfolio.Alliancebernstein boosted its stake in TBPH in the latest quarter, The investment management firm added 25,100 additional shares and now holds a total of 57,839 shares of Theravance Biopharma Inc which is valued at $1,559,339. Ubs Asset Management Americas Inc added TBPH to its portfolio by purchasing 12,019 company shares during the most recent quarter which is valued at $312,013. Zurcher Kantonalbank (zurich Cantonalbank) added TBPH to its portfolio by purchasing 2,372 company shares during the most recent quarter which is valued at $58,399.

Theravance Biopharma Inc closed down -0.32 points or -1.08% at $29.35 with 136,688 shares getting traded on Wednesday. Post opening the session at $29.49, the shares hit an intraday low of $29.08 and an intraday high of $29.81 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Many Wall Street Analysts have commented on Theravance Biopharma Inc. Theravance Biopharma Inc was Downgraded by BofA/Merrill to ” Underperform” on Aug 3, 2016. Guggenheim Initiated Theravance Biopharma Inc on Jun 20, 2016 to “Buy”, Price Target of the shares are set at $30.Company shares were Reiterated by Leerink Partners on Jun 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 29 from a previous price target of $26 .

Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.

Leave a Reply

Theravance Biopharma Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Theravance Biopharma Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.